CONMED (CNMD)
(Delayed Data from NYSE)
$66.59 USD
+0.03 (0.05%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $66.56 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.59 USD
+0.03 (0.05%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $66.56 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Haemonetics (HAE) Q4 Earnings Top Mark, Operating Margin Up
by Zacks Equity Research
A steady momentum in new business wins and consistent geographical expansion drive Haemonetics' (HAE) top-line results
Bruker (BRKR) Q1 Earnings Beat Estimates, Guidance Upbeat
by Zacks Equity Research
Bruker's (BRKR) current focus on product development through higher R&D investment stokes investors' positive sentiment around the stock.
McKesson (MCK) Q4 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
McKesson's (MCK) Q4 results benefit from higher revenues, gross margin expansion and solid show by U.S. Pharmaceutical and Specialty Solutions.
Avanos (AVNS) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Avanos (AVNS) Q1 results benefit from higher revenues, strong segmental performance and expansion in margins.
Allscripts (MDRX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Allscripts (MDRX) Q1 results gain from growth in bookings and solid show by client services segment. Contraction in margins remains a woe.
Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Genomic Health (GHDX) registers strong year-over-year growth in revenues on solid domestic and overseas performances.
Inogen (INGN) Earnings Miss Estimates in Q1, View Lowered
by Zacks Equity Research
Inogen (INGN) slashes revenue and net income guidance for 2019.
DaVita (DVA) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
DaVita (DVA) gains from international revenues in Q1.
Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up
by Zacks Equity Research
Myriad Genetics (MYGN) observes strong year-over-year revenue growth in EndoPredict, Hereditary Cancer and Prolaris testing as well as pharmaceutical and clinical service segments.
Henry Schein's (HSIC) Q1 Earnings, Revenues Beat Estimates
by Urmimala Biswas
Henry Schein's (HSIC) strong share gains in the North American market raise optimism.
Intersect (XENT) Q1 Loss Wider Than Estimates, Revenues Top
by Zacks Equity Research
Intersect (XENT) records revenue growth on increased adoption of the PROPEL family of products and SINUVA Sinus Implant.
QIAGEN's (QGEN) Q1 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
QIAGEN (QGEN) sees year-over-year growth across all segments and majority of geographies.
Masimo (MASI) Q1 Earnings and Revenues Beat, Guidance Solid
by Zacks Equity Research
Solid non-invasive revenues boost Masimo's (MASI) Q1; guidance raised.
Pacific Biosciences (PACB) Incurs Loss in Q1, Revenues Fall
by Zacks Equity Research
Pacific Biosciences' (PACB) segments see softness in Q1; merger with Illumina on track.
Luminex (LMNX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Luminex (LMNX) Q1 results gain from higher revenues from System sales, Royalty as well as Service segments. However, contraction in gross margin remains a woe.
Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) consistently gains traction from its core Medical Devices unit, which witnesses a substantial contribution from the SurVeil pact with Abbott.
Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Fresenius Medical (FMS) gains from solid international revenues in Q1.
HMS Holdings' (HMSY) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Top-line growth, higher commercial and state government revenues and expansion in margins aid HMS Holdings (HMSY) in Q1 earnings. However, increase in cost of services remains a woe.
Integer Holdings (ITGR) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Top-line growth and better performance at Medical and Non-Medical segments benefit Integer Holdings' (ITGR) Q1 results. However, contraction in gross margin remains a dampener.
AMN Healthcare (AMN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Higher revenues and expansion in gross margin find reflection in AMN Healthcare's (AMN) Q1 results. However, weak performance at Nurse and Allied and Locum Tenens segments remain woes.
Globus Medical (GMED) Q1 Earnings Miss, Revenues Grow Y/Y (Revised)
by Zacks Equity Research
Globus Medical (GMED) management states that the first quarter of a year poses a seasonal challenge to the company's capital equipment, which grossly affects its sales in Q1.
DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) Q1 earnings gain from Technology & Equipment unit despite international revenues being down.
Insulet (PODD) Beats Earnings and Revenue Estimates in Q1
by Zacks Equity Research
Insulet (PODD) registers year-over-year improvement in revenues on solid uptake of Omnipod system both in the United States and international markets.
Medidata (MDSO) Q1 Earnings Beat Estimates, Margins fall
by Zacks Equity Research
Medidata (MDSO) witnesses year-over-year revenue growth in double-digits across both operating segments in first-quarter 2019.
PRA Health (PRAH) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
PRA Health's (PRAH) Q1 earnings reflect top-line growth, favorable segmental performance and margin expansion.